Opella Reprices Term Loans, Expects Annual Interest Savings
Opella has successfully repriced its two Term Loan B facilities, totaling approximately €4.97 billion equivalent. The repricing is expected to generate annual interest savings of around €24 million.
Opella announced on May 26th, 2026, the successful repricing of its two 1st Lien Term Loan B facilities, valued collectively at approximately €4.97 billion.
The transaction involved adjustments to both the USD and EUR tranches. The USD-denominated tranche was reduced by $81 million to $3,700 million, while the EUR-denominated tranche was increased by €73 million to €1,780 million. Both tranches benefited from a 50-basis point reduction in margin.
Citi and BNP Paribas served as Global Coordinators for the USD and EUR tranches, respectively. The company stated that the repricing is leverage neutral and does not alter other material terms of the facilities. The financial move is projected to yield annual interest savings of approximately €24 million.
Opella, a global self-care company with a portfolio of over-the-counter products and vitamins, minerals, and supplements, views this transaction as a reflection of continued strong investor demand and confidence in its credit profile. The company operates 13 manufacturing sites and four R&D centers globally.